XPO5 is upregulated in various cancer types, including colorectal cancer (CRC) and prostate adenocarcinoma (PRAD), and its overexpression is associated with unfavorable clinicopathological features and poor patient prognosis (36, 37). Here, XPO5 is linked to prostate adenocarcinoma.